NUMA1 and urinary bladder cancer: The few biomarkers validated in a clinical setting and approved for clinical use by the Food and Drug Administration (FDA) have mostly been discovered with immunological techniques (e.g., Nuclear Matrix Protein 22 (NMP22), Bladder Tumor Antigen (BTA) in bladder cancer) [7].